Table of Contents Author Guidelines Submit a Manuscript
Volume 2012 (2012), Article ID 301975, 18 pages
Review Article

Bone Sarcomas: From Biology to Targeted Therapies

1Department of Oncology for Children and Adolescents, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
2Inserm U957-EA 3822, Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France
3Oncopediatric Departement, CHU de Nantes, Boulevard Jacques Monod, 44093 Nantes, France
4Pediatric Onco-Hematology Department, EA 4438UdS, CHRU Strasbourg, Avenue Molière, 67000 Strasbourg, France
5Unité 830 INSERM, Institut Curie, Centre de Recherche, 26 rue d’Ulm, 75248 Paris Cedex 05, France
6Oncopediatric Departement, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France
7Oncopediatric Departement, Hôpital La Timone, 264 rue Saint Pierre, 13385 Marseille Cedex 5, France
8Department of Medical Oncology, Institut Curie, 26 rue d’Ulm, 75248 Paris Cedex 05, France

Received 1 July 2012; Accepted 10 October 2012

Academic Editor: R. Pollock

Copyright © 2012 Nathalie Gaspar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [17 citations]

The following is the list of published articles that have cited the current article.

  • Joseph Finney, Paul M. Kent, and Marta Batus, “Future directions for pediatric and young adult bone sarcoma,” Current Problems in Cancer, vol. 37, no. 4, pp. 225–235, 2013. View at Publisher · View at Google Scholar
  • Marilyn M. Li, April A. Ewton, and Janice L. Smith, “Using Cytogenetic Rearrangements for Cancer Prognosis and Treatment (Pharmacogenetics),” Current Genetic Medicine Reports, vol. 1, no. 2, pp. 99–112, 2013. View at Publisher · View at Google Scholar
  • Changchun Fan, Xuechun Zhao, and Zhixing Xu, “Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas,” Tumor Biology, 2014. View at Publisher · View at Google Scholar
  • Michel Pinheiro Dos Santos, Caroline Brunetto De Farias, Rafael Roesler, Algemir Lunardi Brunetto, and Ana Lucia Abujamra, “In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: A paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma,” Oncology Reports, vol. 31, no. 2, pp. 955–968, 2014. View at Publisher · View at Google Scholar
  • Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Otto C. Boerman, and Winette T.A. van der Graaf, “Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014. View at Publisher · View at Google Scholar
  • Guiti Eghbali-Fatourechi, “Bisphosphonate therapy in pediatric patients,” Journal of Diabetes & Metabolic Disorders, vol. 13, no. 1, 2014. View at Publisher · View at Google Scholar
  • Mei Li, Ye Zhu, Hongbin Zhang, Lihua Li, Peng He, Hong Xia, Yu Zhang, and Chuanbin Mao, “Delivery of inhibitor of growth 4 (ING4) gene significantly inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells,” Scientific Reports, vol. 4, pp. 7380, 2014. View at Publisher · View at Google Scholar
  • Amrita Banerjee, Sulagna Sanyal, Kirti K Kulkarni, Kuladip Jana, Siddhartha Roy, Chandrima Das, and Dipak Dasgupta, “Anticancer drug mithramycin interacts with core histones: an additional mode of action of the DNA groove binder,” FEBS Open Bio, 2014. View at Publisher · View at Google Scholar
  • Nathalie Gaspar, Douglas S. Hawkins, Uta Dirksen, Ian J. Lewis, Stefano Ferrari, Marie-Cecile Le Deley, Heinrich Kovar, Robert Grimer, Jeremy Whelan, Line Claude, Olivier Delattre, Michael Paulussen, Piero Picci, Kirsten Sundby Hall, Hendrik van den Berg, Ruth Ladenstein, Jean Michon, Lars Hjorth, Ian Judson, Roberto Luksch, Mark L. Bernstein, Perrine Marec-Berard, Bernadette Brennan, Alan W. Craft, Richard B. Womer, Heribert Juergens, and Odile Oberlin, “Ewing Sarcoma: Current Management and Future Approaches Through Collaboration,” Journal Of Clinical Oncology, vol. 33, no. 27, pp. 3036–U140, 2015. View at Publisher · View at Google Scholar
  • S Loschi, C Dufour, O Oberlin, G Goma, D Valteau-Couanet, and N Gaspar, “Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults,” Bone Marrow Transplantation, 2015. View at Publisher · View at Google Scholar
  • Jürgen Sonnemann, Désirée Grauel, Lisa Blümel, Julia Hentschel, Christian Marx, Annelie Blumrich, Katharina Focke, Sabine Becker, Susan Wittig, Sandra Schinkel, Oliver H. Krämer, and James F. Beck, “RETRA exerts anticancer activity in Ewing’s sarcoma cells independent of their TP53 status,” European Journal of Cancer, 2015. View at Publisher · View at Google Scholar
  • Mathilde Penel-Page, Isabelle Ray-Coquard, Julie Larcade, Magali Girodet, Laure Bouclier, Muriel Rogasik, Nadège Corradini, Natacha Entz-Werle, Laurence Brugieres, Julien Domont, Cyril Lervat, Sophie Piperno-Neumann, Helène Pacquement, Jacques-Olivier Bay, Jean-Claude Gentet, Antoine Thyss, Loic Chaigneau, Bérangère Narciso, Helène Cornille, Jean-Yves Blay, and Perrine Marec-Bérard, “Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes),” BMC Cancer, vol. 15, no. 1, 2015. View at Publisher · View at Google Scholar
  • Aude I. Ségaliny, Marta Tellez-Gabriel, Marie-Françoise Heymann, and Dominique Heymann, “Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers,” Journal of Bone Oncology, 2015. View at Publisher · View at Google Scholar
  • Nathalie Garnier, Ray-Coquard, Marec-Berard, Bertrand, Libbrecht, Corradini, Pacquement, Gentet, Lervat, Girodet, and Bouclier, “Use of Off-Label Targeted Therapies in Refractory Sarcomas: Analysis of Pediatric Data from the French Registry Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes,” Journal of Pediatric Biochemistry, vol. 6, no. 3, pp. 136–145, 2016. View at Publisher · View at Google Scholar
  • Bivas Biswas, and Sameer Bakhshi, “Management of Ewing sarcoma family of tumors: Current scenario and unmet need,” World Journal of Orthopaedics, vol. 7, no. 9, pp. 527–538, 2016. View at Publisher · View at Google Scholar
  • Michele Gallo, Annarosaria De Chiara, Ali Munaim Yousif, Concetta Ragone, Maria Letizia Motti, Domenica Rea, Giovanni Botti, Giuseppe Scognamiglio, Vincenzo Ingangi, Flavio Fazioli, Claudio Arra, Paolo Grieco, Maria Vincenza Carriero, Katia Bifulco, and Michele Minopoli, “The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells,” Oncotarget, vol. 7, no. 34, pp. 54474–54487, 2016. View at Publisher · View at Google Scholar
  • Maria Vincenza Carriero, Katia Bifulco, Vincenzo Ingangi, Susan Costantini, Giovanni Botti, Concetta Ragone, Michele Minopoli, Maria Letizia Motti, Domenica Rea, Giosuè Scognamiglio, Gerardo Botti, Claudio Arra, Gennaro Ciliberto, and Antonello Pessi, “Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas,” Scientific Reports, vol. 7, no. 1, 2017. View at Publisher · View at Google Scholar